Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
NCT06445738 · View on ClinicalTrials.gov ↗
Study Summary
The PROSPECTIVE trial aims to find out if using the results of Magnetic Resonance Imaging (MRI) for early breast cancer can select people to not have radiotherapy and still have a low chance of the cancer coming back after surgery. The main question it aims to answer is: \* Will cancer come back in the same breast as the original cancer in patients who have surgery for their breast cancer, but who don't have radiotherapy afterwards because the results of an MRI before surgery showed favourable characteristics for not having radiotherapy.
Conditions Studied
Interventions
- RADIATION Arm A: Radiotherapy Omission
- OTHER Arm B: Standard Treatment
Study Locations (9)
New South Wales
- The Chris O'Brien Lifehouse — Camperdown
- Lake Macquarie Private Hospital — Gateshead
- Mater Hospital, Sydney — North Sydney
- Westmead Hospital — Westmead
Victoria
- Monash Cancer Centre (MMC Moorabbin) — Clayton
- The Royal Melbourne Hospital — Melbourne
California
- UCSF Breast Care Center — San Francisco
Texas
- Baylor St Luke's Medical Centre — Houston
South Australia
- Royal Adelaide Hospital — Adelaide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2025-06-06 |
| Est. Completion | 2039-06 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06445738
The ClinicalTrials.gov registry entry for NCT06445738 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Breast Cancer Trials, Australia and New Zealand, which has 29 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions — of which Arm A: Radiotherapy Omission is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06445738 reports 9 study locations spanning 5 distinct geographic areas — top geographies include New South Wales, Victoria, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06445738 about?
NCT06445738 is a clinical study titled "Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)". The PROSPECTIVE trial aims to find out if using the results of Magnetic Resonance Imaging (MRI) for early breast cancer can select people to not have radiotherapy and still have a low chance of the cancer coming back after surgery. The main question it aims to answer is: \* Will cancer come back i...
What is the current status of trial NCT06445738?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,400 participants. The study started on 2025-06-06. Estimated completion is 2039-06.
What conditions does trial NCT06445738 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Cancer Female. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06445738?
The interventions under investigation include: Arm A: Radiotherapy Omission (RADIATION), Arm B: Standard Treatment (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06445738?
This trial is sponsored by Breast Cancer Trials, Australia and New Zealand, which has 29 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06445738 being conducted?
This trial has 9 study locations across California, Texas, New South Wales, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.